Genetic aspects of vitamin D receptor and metabolism in relation to the risk of multiple sclerosis

General Physiology and Biophysics

Volumn 32, Issue 4, 2013, Pages 459-466

  Krizova, Lucia ^a   Kollar, Branislav ^a   Jezova, Daniela ^b   Turcani, Peter ^a  

^a Comenius University ^*  (Slovakia)

^b INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

Author keywords

Genetic variants; Multiple sclerosis risk; Vitamin D deficiency; Vitamin D supplementation

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; COLECALCIFEROL; CYTOCHROME P450; CYTOCHROME P450 27B1; ERGOCALCIFEROL; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D RECEPTOR;

CD4+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; GENE EXPRESSION; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; IMMUNOMODULATION; MULTIPLE SCLEROSIS; PREDICTOR VARIABLE; REVIEW; SIGNAL TRANSDUCTION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION;

DIETARY SUPPLEMENTS; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; MULTIPLE SCLEROSIS; RECEPTORS, CALCITRIOL; VITAMIN D;

EID: 84893711746     PISSN: 02315882     EISSN: 13384325     Source Type: Journal    
DOI: 10.4149/gpb_2013067     Document Type: Review

References (48)

1. Ahn J., Yu K., Stolzenberg-Solomon R., Simon K. C., McCullough M. L., Gallicchio L., Jacobs E. J., Ascherio A., Helzlsouer K., Jacobs K. B. et al. (2010): Genome-wide association study of circulating vitamin D levels. Hum. Mol. Genet. 19, 2739-2745 http://dx.doi.org/10.1093/hmg/ddq155
2. Alloza I., Otaegui D., de Lapuente A. L., Antigüedad A., Varadé J., Nú-ez C., Arroyo R., Urcelay E., Fernandez O., Leyva L. et al. (2012): ANKRD55 and DHCR7 are novel multiple sclerosis risk loci. Genes Immun. 13, 253-257 http://dx.doi.org/10.1038/gene.2011.81
3. Ascherio A., Munger K. L., Lünemann J. D. (2012): The initiation and prevention of multiple sclerosis. Nat. Rev. Neurol. 8, 602-612 http://dx.doi.org/10.1038/nrneurol.2012.198
4. Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene) (2009): Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat. Genet. 41, 824-828 http://dx.doi.org/10.1038/ng.396
5. Ban M., Caillier S., Mero I. L., Myhr K. M., Celius E. G., Aarseth J., Torkildsen Ø., Harbo H. F., Oksenberg J., Hauser S. L. et al. (2013): No evidence of association between mutant alleles of the CYP27B1 gene and multiple sclerosis. Ann. Neurol. 73, 430-432 http://dx.doi.org/10.1002/ana.23833
6. Baranzini S. E., Nickles D. (2012): Genetics of multiple sclerosis: swimming in an ocean of data. Curr. Opin. Neurol. 25, 239-245 http://dx.doi.org/10.1097/WCO.0b013e3283533a93
7. Barizzone N., Pauwels I., Luciano B., Franckaert D., Guerini F. R., Cosemans L., Hilven K., Salviati A., Dooley J., Danso-Abeam D. et al. (2013): No evidence for a role of rare CYP27B1 functional variations in multiple sclerosis. Ann. Neurol. 73, 433-437 http://dx.doi.org/10.1002/ana.23834
8. Bartanusz V., Jezova D., Alajajian B., Digicaylioglu M. (2011): The blood-spinal cord barrier: morphology and clinical implications. Ann. Neurol. 70, 194-206 http://dx.doi.org/10.1002/ana.22421
9. Buc M. (2013): Multiple sclerosis - Role of regulatory T cells in the pathogenesis and biological therapy of the disease. Cesk. Slov. Neurol. Neurochir. 76, 293-299
10. Castro-Borrero W., Graves D., Frohman T. C. Flores A. B., Hardeman P., Logan D., Orchard M., Greenberg B., Frohman E. M. et al. (2012): Current and emerging therapies in multiple sclerosis: a systematic review. Ther. Adv. Neurol. Disord. 5, 205-220 http://dx.doi.org/10.1177/1756285612450936
11. Cheng J. B., Levine M. A., Bell N. H. Mangelsdorf D. J., Russell D. W. et al. (2004): Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc. Natl. Acad. Sci. U.S.A. 101, 7711-7715 http://dx.doi.org/10.1073/pnas.0402490101
12. Chhabra N. (2012): Vitamin D - subjective questions and rickets. A Case Oriented Approach Towards Biochemistry (London), Biochemistry for Medics
13. Cooper J. D., Smyth D. J., Walker N. M., Stevens H., Burren O. S., Wallace C., Greissl C., Ramos-Lopez E., Hyppönen E., Dunger D. B. et al. (2011): Inherited variation in vitamin D genes is associated with predisposition to autoimmune disease type 1 diabetes. Diabetes 60, 1624-1631 http://dx.doi.org/10.2337/db10-1656
14. Correale J., Ysrraelit M. C., Gaitán M. I. (2009): Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain 132, 1146-1160 http://dx.doi.org/10.1093/brain/awp033
15. Dörr J., Ohlraun S., Skarabis H., Paul F. (2012): Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial. Trials 13, 15 http://dx.doi.org/10.1186/1745- 6215-13-15
16. Filippini G., Del Giovane C., Vacchi L. D'Amico R., Di Pietrantonj C., Beecher D., Salanti G. (2013): Immunomodulators and immunosuppressants for multiple sclerosis: a network metaanalysis. Cochrane Database Syst. Rev. 6, CD008933
17. Franklin R. J., Ffrench-Constant C., Edgar J. M., Smith K. J. (2012): Neuroprotection and repair in multiple sclerosis. Nat Rev Neurol. 8, 624-634 http://dx.doi.org/10.1038/nrneurol.2012.200
18. Holick M. F. (2003): Vitamin D: A millenium perspective. J. Cell. Biochem. 88, 296-307 http://dx.doi.org/10.1002/jcb.10338
19. Holmøy T., Torkildsen O., Myhr K. M., Løken-Amsrud K. I. (2012): Vitamin D supplementation and monitoring in multiple sclerosis: who, when and wherefore. Acta Neurol. Scand. Suppl. 195, 63-69 http://dx.doi.org/10. 1111/ane.12028
20. Huang J., Xie Z. F. (2012): Polymorphisms in the vitamin D receptor gene and multiple sclerosis risk: a meta-analysis of case-control studies. J. Neurol. Sci. 313, 79-85 http://dx.doi.org/10.1016/j.jns.2011.09.024
21. International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2. (2011): Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476, 214-219 http://dx.doi.org/10.1038/nature10251
22. Jongen P. J., Ter Horst A. T., Brands A. M. (2012): Cognitive impairment in multiple sclerosis. Minerva Med. 103, 73-96
23. Kipp M., van der Valk P., Amor S. (2012): Pathology of multiple sclerosis. CNS Neurol Disord. Drug Targets 11, 506-517 http://dx.doi.org/10. 2174/187152712801661248
24. Krizova L., Kollar B., Carnicka Z., Siarnik P., Jezova D., Turcani P. (2013): genetic and environmental factors involved in the pathogenesis of multiple sclerosis. Cesk. Slov. Neurol. Neurochir. 76, 430-437 (in Slovak)
25. Miller E. (2012): Multiple sclerosis. Adv. Exp. Med. Biol. 724, 222-238 http://dx.doi.org/10.1007/978-1-4614-0653-2-17
26. Mirzaei F., Michels K. B., Munger K., O'Reilly E., Chitnis T., Forman M. R., Giovannucci E., Rosner B., Ascherio A. (2011): Gestational vitamin D and the risk of multiple sclerosis in offspring. Ann. Neurol. 70, 30-40 http://dx.doi.org/10.1002/ana.22456
27. Munger K. L., Zhang S. M., O'Reilly E. Hernán M. A., Olek M. J., Willett W. C., Ascherio A. (2004): Vitamin D intake and incidence of multiple sclerosis. Neurology 62, 60-65 http://dx.doi.org/10.1212/01.WNL.0000101723. 79681.38
28. Munger K. L., Levin L. I., Hollis, B. W., Howard N. S., Ascherio A. (2006): Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296, 2832-2838 http://dx.doi.org/10.1001/jama.296.23.2832
29. Munger K. L., Chitnis T., Frazier A. L., Giovannucci E., Spiegelman D., Ascherio A. (2011): Dietary intake of vitamin D during adolescence and risk of multiple sclerosis. J. Neurol. 258, 479-485 http://dx.doi.org/10.1007/s00415- 010-5783-1
30. Nick S. T., Roberts C., Billiodeaux S., Davis D. E., Zamanifekri B., Sahraian M. A., Alekseeva N., Munjampalli S., Roberts J., Minagar A. et al. (2012): Multiple sclerosis and pain. Neurol. Res. 34, 829-841 http://dx.doi.org/10.1179/1743132812Y.0000000082
31. Nieves J., Cosman F., Herbert J., Shen V., Lindsay R. (1994): High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 44, 1687-1692 http://dx.doi.org/10.1212/WNL.44.9.1687
32. Pierrot-Deseilligny C., Souberbielle J. C. (2010): Is hypovitaminosis D one of the environmental risk factors for multiple sclerosis? Brain 133, 1869-1888 http://dx.doi.org/10.1093/brain/awq147
33. Pierrot-Deseilligny C., Souberbielle J. C. (2013): Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis. Ther. Adv. Neurol. Disord. 6, 81-116 http://dx.doi.org/10.1177/1756285612473513
34. Ramagopalan S. V., Maugeri N. J., Handunnetthi L., Lincoln M. R., Orton S. M., Dyment D. A., Deluca G. C., Herrera B. M., Chao M. J., Sadovnick A. D. (2009): Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB11501 is regulated by vitamin D. PLoS Genet. 5, e1000369 http://dx.doi.org/10.1371/journal.pgen.1000369
35. Ramagopalan S. V., Heger A., Berlanga A. J., Maugeri N. J., Lincoln M. R., Burrell A., Handunnetthi L., Handel A. E., Disanto G., Orton S. M. et al. (2010): ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res. 20, 1352-1360 http://dx.doi.org/10.1101/gr.107920.110
36. Ramagopalan S. V., Dyment D. A., Cader M. Z., Morrison K. M., Disanto G., Morahan J. M., Berlanga-Taylor A. J., Handel A., De Luca G. C., Sadovnick A. D. et al. (2011): Rare variants in the CYP27B1 gene are associated with multiple sclerosis. Ann. Neurol. 70, 881-886 http://dx.doi.org/10.1002/ana.22678
37. Sá M. J. (2012): Physiopathology of symptoms and signs in multiple sclerosis. Arq. Neuropsiquiatr. 70, 733-740 http://dx.doi.org/10.1590/S0004- 282X2012000900016
38. Salzer J., Hallmans G., Nyström M., Stenlund H., Wadell G., Sundström P. (2012): Vitamin D as protective factor in multiple sclerosis. Neurology 79, 2140-2145 http://dx.doi.org/10.1212/WNL.0b013e3182752ea8
39. Simon K. C., Munger K. L., Kraft P., Hunter D. J., De Jager P. L., Ascherio A. (2011): Genetic predictors of 25-hydroxyvitamin D levels and risk of multiple sclerosis. J. Neurol. 258, 1676-1682 http://dx.doi.org/10.1007/s00415- 011-6001-5
40. Smolders J., Thewissen M., Peelen E., Menheere P., Tervaert J. W., Damoiseaux J., Hupperts R. (2009): Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS One 4, e6635 http://dx.doi.org/10.1371/journal.pone.0006635
41. Smolders J., Peelen E., Thewissen M., Menheere P., Tervaert J. W., Damoiseaux J., Hupperts R. (2010): Safety and T cell modulating effects of high dose vitamin D3 supplementation in multiple sclerosis. PLoS One 5, e15235 http://dx.doi.org/10.1371/journal.pone.0015235
42. Smolders J., Hupperts R., Barkhof F., Grimaldi L. M., Holmoy T., Killestein J., Rieckmann P., Schluep M., Vieth R., Hostalek U. et al. (2011): Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, doubleblind, randomized, placebo-controlled trial. J. Neurol. Sci. 311, 44-49 http://dx.doi.org/10.1016/j.jns.2011.04.013
43. Soilu-Hänninen M., Aivo J., Lindström B. M., Elovaara I., Sumelahti M. L., Färkkilä M., Tienari P., Atula S., Sarasoja T., Herrala L. et al. (2012): A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis. J. Neurol. Neurosurg. Psychiatr. 83, 565-571 http://dx.doi.org/10.1136/jnnp-2011-301876
44. Staples J., Ponsonby A. L., Lim L. (2010): Low maternal exposure to ultraviolet radiation in pregnancy, month ofbirth, and risk of multiple sclerosis in offspring: longitudinal analysis. BMJ 340, c1640
45. Stein M. S., Liu Y., Gray O. M., Baker J. E., Kolbe S. C., Ditchfield M. R., Egan G. F., Mitchell P. J., Harrison L. C., Butzkueven H. et al. (2011): A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 77, 1611-1618 http://dx.doi.org/10.1212/WNL. 0b013e3182343274
46. Uitterlinden A. G., Fang Y., Van Meurs J. B., Pols H. A., Van Leeuwen J. P. (2004): Genetics and biology of vitamin D receptor polymorphisms. Gene 338, 143-156 http://dx.doi.org/10.1016/j.gene.2004.05.014
47. Weber M. S., Menge T., Lehmann-Horn K., Kronsbein H. C., Zettl U., Sellner J., Hemmer B., Stüve O. (2012): Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects. Curr. Pharm. Des. 18, 209-219 http://dx.doi.org/10.2174/138161212799040501
48. Willer C. J., Dyment D. A., Sadovnick A. D., Rothwell P. M., Murray T. J., Ebers G. C.; Canadian Collaborative Study Group. (2005): Timing of birth and risk of multiple sclerosis: population based study. BMJ 330, 120 http://dx.doi.org/10.1136/bmj.38301.686030.63